Skip to main content
Frances Collichio, MD, Oncology, Chapel Hill, NC

Frances A Collichio MD


Clinical Professor of Hematology & Oncology, University of North Carolina School of Medicine

Join to View Full Profile
  • 101 Manning DrChapel Hill, NC 27514

  • Phone+1 919-966-4996

  • Fax+1 919-843-5515

Dr. Collichio is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Rochester Medical Center
    University of Rochester Medical CenterFellowship, Hematology and Medical Oncology, 1992
  • University of Rochester Medical Center
    University of Rochester Medical CenterResidency, Internal Medicine, 1987 - 1990
  • University of Rochester School of Medicine and Dentistry
    University of Rochester School of Medicine and DentistryClass of 1987

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1998 - 2025
  • NY State Medical License
    NY State Medical License 1988 - 1999
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • ASCO Education Council 2017-2018
  • Regional Top Doctor Castle Connolly, 2014
  • Co-Chair ASH/ASCO Curricular Milestones Commitee ASH and ASCO
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Milestones 2.0 and Harmonized Milestones 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Parental Leave in Graduate Medical Education: Recommendations for Reform
    Parental Leave in Graduate Medical Education: Recommendations for ReformNovember 29th, 2018
  • Revolutionizing Immune and Target Therapies
    Revolutionizing Immune and Target TherapiesSeptember 17th, 2015
  • Injecting Genetically Modified Virus into Tumor May Treat Metastatic Melanoma
    Injecting Genetically Modified Virus into Tumor May Treat Metastatic MelanomaJanuary 31st, 2019

Grant Support

  • Clinical Trial: Lccc 0424: Phase I Erlotinib Given Every 72 Hours To Patients WNational Center For Research Resources2008

Committees

  • Member, ACGME Hematology Oncology Milestones 2018 - 2018

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: